Direct delivery into circulation allows the peptide to reach target tissues without the absorption loss associated with oral forms
Research Applications This selective activity makes AOD9604 an attractive candidate for obesity treatment and body composition optimization research, as it theoretically provides the metabolic benefits of growth hormone for fat reduction without the growth-promoting effects that could stimulate cancer cell proliferation, cause acromegaly-like symptoms, or induce insulin resistance
dollars unless stated otherwise and may change without notice
A typical blend dosage might look like: BPC-157: 250500 mcg per day TB-500: 22.5 mg twice per week during the loading phase (first 2 weeks), then 2 mg once per week for maintenance Precise calculation depends on your body weight, injury type, and overall protocol
Tirzepatide gastric emptying and the oral-drug interaction GLP-1R-mediated delay at 4.5-5 mg, tachyphylaxis by about 4 weeks, re-engagement on escalation
The isoprenaline-induced myocardial infarction model showed reduced infarct size with BPC-157 treatment